CEL-SCI’s Lead Head & Neck Cancer Candidate Shows 43% Survival Extension
CEL-SCI Corporation (NASDAQ:CVM) reported new data from its pivotal Phase 3 study of Multikine (Leukocyte Interleukin) in newly diagnosed locally advanced…
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Gainers
ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland.
Tesla To $250? Here Are 10 Other Price Target Changes For Thursday
Morgan Stanley cut Tesla, Inc. (NASDAQ: TSLA) price target from $330 to $250. Morgan Stanley analyst Adam Jonas maintained an Overweight rating on the stock. Tesla shares rose 4.4% to $117.65 in pre-market trading.
EF Hutton Maintains Buy on CEL-SCI, Lowers Price Target to $16
EF Hutton analyst Tim Moore maintains CEL-SCI (AMEX:CVM) with a Buy and lowers the price target from $17 to $16.
Stocks That Hit 52-Week Lows On Thursday
Thursday's session saw 329 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 293 companies set new 52-week lows.
10-Year Phase 3 Trial Shows CEL-SCI’s Multikine immunotherapy Extends Lives In Head & Neck Cancer Patients
CEL-SCI Corporation (NYSE:CVM) said that its 10-year Phase 3 trial showed that Multikine immunotherapy significantly extended the lives of patients with…
Cel-Sci Corp Says Phase 3 Trial Showed Multikine Immunotherapy Extended Lives Of Patients With Locally Advanced Primary SCCHN
CEL-SCI Corporation (NYSE:CVM) today issued a letter to its shareholders.
Dear CEL-SCI Shareholders:
I wanted to write to update you on our progress. Our story is following the well-worn path of all
Cel-Sci Corporation Issues Letter to Shareholders; Multikine Reduced And Eliminated Tumors Within 3 Weeks; Nearly 4-Year Median Overall Survival Benefit In The Radiation-Only Group; Data Presentations At ASCO And ESMO
Multikine® reduced and eliminated tumors within 3 weeks and before surgery
Nearly 4-year median overall survival benefit in the radiation-only group
Data presentations at ASCO and ESMO world-leading peer review
CVM: ClinicalTrials Submission
By John Vandermosten, CFA
NYSE:CVM
READ THE FULL CVM RESEARCH REPORT